Product Pipeline

 

Pre-Clinical


Phase 1

Phase 2

Phase 3


 

PV-10 and Keytruda®: Melanoma (Metastatic Melanoma; NCT02557321)

 
 

PV-10:  Cancer Metastatic to the Liver (Expanded: a basket study; NCT00986661)

 
 

PV-10:  Cancer Metastatic to the Liver (Metastatic Uveal Melanoma; NCT00986661)

 

 

PV-10:  Cancer Metastatic to the Liver (Neuroendocrine Tumors [NET]; NCT02693067)

 

 

PV-10:  Pediatric Solid Tumors

 

 

PH-10: Inflammatory Dermatoses

  • (Extended 12-week Administration Proof-of-Concept)
 

Warnings

US law and regulations require that unapproved drug products be investigated and ultimately approved in compliance with the Food & Drug Administration's Investigational New Drug Application (IND) requirements. Provectus is currently authorized to test Rose Bengal in our PV-10 and PH-10 formulations in clinical studies following protocols compliant with the IND process. Provectus cautions that it is unlawful and potentially harmful for individuals to attempt to use Rose Bengal for treatment of cancer or dermatologic disorders outside regulated clinical trials.

NEWSLETTER
Errors